We report a case of Guillain-Barré syndrome (GBS) following the first dose of 
Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the 
COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have 
been increasingly reported. After reviewing the available literature, 
considering the annual incidence of GBS, in this historical moment, the public 
health systems cannot afford an unjustified distrust in vaccines, caused by 
misinterpretation of epidemiological data. Nonetheless, it is important for 
clinicians to promptly recognize neurological complications potentially 
associated with COVID-19 vaccinations and report them to pharmacovigilance 
agencies.